{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:46:19Z","timestamp":1792176379761,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41433-026-04685-w","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:22:50Z","timestamp":1784262170000},"page":"2341-2348","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Azithromycin versus azithromycin-pyrimethamine and sulfadiazine-pyrimethamine for the treatment of ocular toxoplasmosis: a retrospective comparative case-series"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9914-2775","authenticated-orcid":false,"given":"Marcela","family":"Bohn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5297-2301","authenticated-orcid":false,"given":"Tjebo F. C.","family":"Heeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isuru","family":"de Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Ajamil-Rodanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4662-2994","authenticated-orcid":false,"given":"Harry","family":"Petrushkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"4685_CR1","first-page":"973","volume":"136","author":"GN Holland","year":"2003","unstructured":"Holland GN. Ocular toxoplasmosis: a global reassessment. Part 1: Epidemiol course Dis Am J Ophthalmol. 2003;136:973\u201388.","journal-title":"Part 1: Epidemiol course Dis Am J Ophthalmol"},{"key":"4685_CR2","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1590\/S0074-02762009000200030","volume":"104","author":"AG Commodaro","year":"2009","unstructured":"Commodaro AG, Belfort RN, Rizzo LV, et al. Ocular toxoplasmosis\u2014An update and review of the literature. Mem do Inst Oswaldo Cruz. 2009;104:345\u201350.","journal-title":"Mem do Inst Oswaldo Cruz"},{"key":"4685_CR3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1136\/bjo.77.6.371","volume":"77","author":"A Rothova","year":"1993","unstructured":"Rothova A. Ocular involvement in toxoplasmosis. Br J Ophthalmol. 1993;77:371\u20137.","journal-title":"Br J Ophthalmol"},{"key":"4685_CR4","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S0161-6420(02)00990-9","volume":"109","author":"LEH Bosch-Driessen","year":"2002","unstructured":"Bosch-Driessen LEH, Berendschot TTJM, Ongkosuwito JV, Rothova A. Ocular toxoplasmosis: Clinical features and prognosis of 154 patients. Ophthalmology. 2002;109:869\u201378.","journal-title":"Ophthalmology"},{"key":"4685_CR5","doi-asserted-by":"publisher","unstructured":"Gilbert RE, Harden M, Stanford M Antibiotics versus control for toxoplasma retinochoroiditis. In: Gilbert RE, ed. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd; 2002. https:\/\/doi.org\/10.1002\/14651858.CD002218.","DOI":"10.1002\/14651858.CD002218"},{"key":"4685_CR6","first-page":"5","volume":"2016","author":"E Pradhan","year":"2016","unstructured":"Pradhan E, Bhandari S, Gilbert RE, Stanford M. Antibiotics versus no treatment for toxoplasma retinochoroiditis. Cochrane Database Syst Rev. 2016;2016:5.","journal-title":"Cochrane Database Syst Rev"},{"key":"4685_CR7","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/S0161-6420(03)00083-6","volume":"110","author":"MR Stanford","year":"2003","unstructured":"Stanford MR, See SE, Jones LV, Gilbert RE. Antibiotics for toxoplasmic retinochoroiditis: an evidence-based systematic review. Ophthalmology. 2003;110:926\u201332.","journal-title":"Ophthalmology"},{"key":"4685_CR8","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1136\/bjo.82.8.858","volume":"82","author":"LH Bosch-Driessen","year":"1998","unstructured":"Bosch-Driessen LH, Rothova A. Sense and nonsense of corticosteroid administration in the treatment of ocular toxoplasmosis. Br J Ophthalmol. 1998;82:858\u201360.","journal-title":"Br J Ophthalmol"},{"key":"4685_CR9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/S0002-9394(02)01526-X","volume":"134","author":"GN Holland","year":"2002","unstructured":"Holland GN, Lewis KG. An update on current practices in the management of ocular toxoplasmosis. Am J Ophthalmol. 2002;134:102\u201314.","journal-title":"Am J Ophthalmol"},{"key":"4685_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/09273948.2016.1215471","volume":"26","author":"FB Morais","year":"2018","unstructured":"Morais FB, Arantes TEFE, Muccioli C. Current practices in ocular toxoplasmosis: a survey of Brazilian uveitis specialists. Ocul Immunol Inflamm. 2018;26:317\u201323.","journal-title":"Ocul Immunol Inflamm"},{"key":"4685_CR11","first-page":"1","volume":"31","author":"IR Dunay","year":"2018","unstructured":"Dunay IR, Gajurel K, Dhakal R, Liesenfeld O, Montoya JG. Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice. Clin Microbiol Infect. 2018;31:1\u201333.","journal-title":"Clin Microbiol Infect"},{"key":"4685_CR12","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.ajo.2015.04.005","volume":"159","author":"ME Grigg","year":"2015","unstructured":"Grigg ME, Dubey JP, Nussenblatt RB. Ocular toxoplasmosis: lessons from Brazil. Am J Ophthalmol. 2015;159:999\u20131001.","journal-title":"Am J Ophthalmol"},{"key":"4685_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.18773\/austprescr.2015.030","volume":"38","author":"BK McMullan","year":"2015","unstructured":"McMullan BK, Mostaghim M. Prescribing azithromycin. Aust Prescriber. 2015;38:87\u201389.","journal-title":"Aust Prescriber"},{"key":"4685_CR14","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1136\/bjo.82.11.1306","volume":"82","author":"A Rothova","year":"1998","unstructured":"Rothova A, Bosch-Driessen LEH, Van Loon NH, Treffers WF. Azithromycin for ocular toxoplasmosis. Br J Ophthalmol. 1998;82:1306\u20138.","journal-title":"Br J Ophthalmol"},{"key":"4685_CR15","unstructured":"Ghavidel L, Milani A, And MBCJ of M, 2017 U. Comparison of azithromycin and pyrimethamine\/sulfadiazine treatment in ocular toxoplasmosis in North West of Iran. Crescent J Med Biol Sci. 2017;4:80\u201384."},{"key":"4685_CR16","doi-asserted-by":"publisher","first-page":"296","DOI":"10.12659\/MSM.882735","volume":"18","author":"K Balaskas","year":"2012","unstructured":"Balaskas K, Vaudaux J, Boillat-Blanco N, Guex-Crosier Y. Azithromycin versus sulfadiazine and pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: A pilot study. Med Sci Monit. 2012;18:296\u2013302.","journal-title":"Med Sci Monit"},{"key":"4685_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S0002-9394(02)01537-4","volume":"134","author":"LH Bosch-Driessen","year":"2002","unstructured":"Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MSA, et al. A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Am J Ophthalmol. 2002;134:34\u201340.","journal-title":"Am J Ophthalmol"},{"key":"4685_CR18","unstructured":"Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H RD the CG. The CARE Guidelines: Consensus-Based Clinical Case Reporting Guideline Development."},{"key":"4685_CR19","unstructured":"Horizon Strategic Partners Ltd. MicroGuide (App). Moorfields Emergency Guidelines App > Uveitis and endophthalmitis > Toxoplasma Chorioretinitis (last version 2019). New version available at Eolas Medical (App)."},{"key":"4685_CR20","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.r-project.org\/."},{"key":"4685_CR21","unstructured":"Heeren T eye package for R (VA converter). https:\/\/va-converter.com\/."},{"key":"4685_CR22","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1167\/iovs.05-0981","volume":"47","author":"K Schulze-Bonsel","year":"2006","unstructured":"Schulze-Bonsel K, Feltgen N, Burau H, Hansen L, Bach M. Visual Acuities \u201cHand Motion\u201d and \u201cCounting Fingers\u201d Can Be Quantified with the Freiburg Visual Acuity Test. Investig Opthalmol Vis Sci. 2006;47:1236.","journal-title":"Investig Opthalmol Vis Sci"},{"key":"4685_CR23","doi-asserted-by":"publisher","unstructured":"Therneau TM, Grambsch PM Modeling Survival Data: Extending the Cox Model.; 2000. https:\/\/doi.org\/10.1002\/sim.956.","DOI":"10.1002\/sim.956"},{"key":"4685_CR24","doi-asserted-by":"publisher","unstructured":"Venables WN, Ripley BD. Modern Applied Statistics with S. Springer New York; 2002. https:\/\/doi.org\/10.1007\/978-0-387-21706-2.","DOI":"10.1007\/978-0-387-21706-2"},{"key":"4685_CR25","first-page":"1","volume":"137","author":"GN Holland","year":"2004","unstructured":"Holland GN. Ocular toxoplasmosis: a global reassessment. Part II: Dis Manif Manag Am J Ophthalmol. 2004;137:1\u201317.","journal-title":"Part II: Dis Manif Manag Am J Ophthalmol"},{"key":"4685_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0002-9394(02)01527-1","volume":"134","author":"C Silveira","year":"2002","unstructured":"Silveira C, Belfort R, Muccioli C, et al. The effect of long-term intermittent trimethoprim\/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol. 2002;134:41\u201346.","journal-title":"Am J Ophthalmol"},{"key":"4685_CR27","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1128\/AAC.32.4.524","volume":"32","author":"HR Chang","year":"1988","unstructured":"Chang HR, Pech\u00e8re JC. In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii. Antimicrob Agents Chemother. 1988;32:524\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"4685_CR28","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1093\/jpp\/rgac059","volume":"74","author":"H Daniel","year":"2022","unstructured":"Daniel H, Louisa M, Edwar L. Azithromycin concentration in rabbits\u2019 plasma and posterior segment of the eyes following oral drug administration: a dose-finding study for the application in ocular toxoplasmosis. J Pharm Pharmacol. 2022;74:1743\u20138.","journal-title":"J Pharm Pharmacol"},{"key":"4685_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-12-132","volume":"12","author":"LS Castro-Filice","year":"2014","unstructured":"Castro-Filice LS, Barbosa BF, Angeloni MB, et al. Azithromycin is able to control Toxoplasma gondii infection in human villous explants. J Transl Med. 2014;12:132.","journal-title":"J Transl Med"},{"key":"4685_CR30","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s40261-022-01203-0","volume":"42","author":"R Antonucci","year":"2022","unstructured":"Antonucci R, Cuzzolin L, Locci C, Dessole F, Capobianco G. Use of azithromycin in pregnancy: more doubts than certainties. Clin Drug Investig. 2022;42:921\u201335.","journal-title":"Clin Drug Investig"},{"key":"4685_CR31","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/infdis\/164.1.170","volume":"164","author":"J Huskinson-Mark","year":"1991","unstructured":"Huskinson-Mark J, Araujo FG, Remington JS. Evaluation of the effect of drugs on the cyst form of toxoplasma gondii. J Infect Dis. 1991;164:170\u20137.","journal-title":"J Infect Dis"},{"key":"4685_CR32","first-page":"251584141878362","volume":"10","author":"KA Kagkelaris","year":"2018","unstructured":"Kagkelaris KA, Makri OE, Georgakopoulos CD, Panayiotakopoulos GD. An eye for azithromycin: review of the literature. Ther Adv Ophthalmol. 2018;10:251584141878362.","journal-title":"Ther Adv Ophthalmol"},{"key":"4685_CR33","first-page":"318","volume":"7","author":"ZS Almalki","year":"2014","unstructured":"Almalki ZS, Guo JJ. Cardiovascular events and safety outcomes associated with azithromycin therapy: a meta-analysis of randomized controlled trials. Am Health Drug Benefits. 2014;7:318\u201328.","journal-title":"Am Health Drug Benefits"},{"key":"4685_CR34","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1128\/AAC.37.9.1993","volume":"37","author":"L Cantin","year":"1993","unstructured":"Cantin L, Chamberland S. In vitro evaluation of the activities of azithromycin alone and combined with pyrimethamine against Toxoplasma gondii. Antimicrob Agents Chemother. 1993;37:1993\u20136.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04685-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04685-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04685-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:55:40Z","timestamp":1792173340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04685-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":34,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4685"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04685-w","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"26 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study involves human participants and was approved by an Ethics Committee(s) or Institutional Board(s). Approved by Moorfields Eye Hospital Clinical Audit Committee with the registration CA20\/UV\/213.2.","order":2,"name":"Ethics","label":"Ethics statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}